Advances in the Diagnosis and Individualized Treatment of MDS: Molecular Testing, Emerging Therapies, and AML Commonalities
Advances in the Diagnosis and Individualized Treatment of MDS: Molecular Testing, Emerging Therapies, and AML Commonalities is organized by Paradigm Medical Communications, LLC.
Release Date: March 31, 2023
Expiration Date: March 31, 2024
Program Overview :
The management of MDS is evolving, with the publication and adoption of the International Prognostic Scoring System-Molecular (IPSS-M), which now includes molecular testing results for prognostication. In addition, the treatment of MDS is poised to change as well, as several emerging agents have demonstrated promising results in early phase trials and are now being evaluated in phase 3 studies. Given this, new questions have arisen about risk stratification and treatment selection now and in the future for higher-risk MDS. In addition, the high similarity between TP53-mutated MDS and AML suggests that they are a single entity that can be treated similarly. This interactive infographic will engage learners in a multimedia journey about the latest updates on the management of higher-risk MDS and the overlap between MDS and AML with mutated TP53.
Learning Objectives:
Upon completion of this activity, participants should be able to:
• Apply molecular testing results into prognostication of MDS using the IPSS-M system as it relates to treatment planning
• Outline the emerging therapies in the late stages of development for the treatment of higher-risk MDS, including mechanisms of action, clinical trials, and any efficacy and safety data
• Describe the overlap between higher-risk MDS and AML, particularly as it relates to the treatment of TP53-mutated disease